Savara (NASDAQ:SVRA) Issues Earnings Results

Savara (NASDAQ:SVRA) posted its earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11), Zacks reports.

Savara Price Performance

NASDAQ SVRA opened at $3.25 on Thursday. The company’s 50 day simple moving average is $3.96 and its two-hundred day simple moving average is $4.22. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. Savara has a 1 year low of $3.24 and a 1 year high of $5.70.

Analysts Set New Price Targets

Several research analysts recently commented on SVRA shares. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. Evercore ISI reaffirmed an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday. Finally, HC Wainwright decreased their price objective on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and an average target price of $10.17.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.